- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | RedChip Companies, Inc.: Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9 | 379 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / June 5, 2026 / RedChip Companies will host an investor webinar with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) ("Calidi" or "the Company") on June 9, 2026, at... ► Artikel lesen | |
| 29.05. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 26.05. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 23.05. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Provides Required NYSE American Disclosure | 187 | GlobeNewswire (Europe) | SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines... ► Artikel lesen | |
| 14.05. | Calidi BioTherapeutics GAAP EPS of -$0.43 | 1 | Seeking Alpha | ||
| 14.05. | Calidi Biotherapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| CALIDI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.05. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights | 235 | GlobeNewswire (Europe) | Presented new data on CLD-401 at the AACR conference in San Diego, CA, detailing the profound immune changes in the tumor microenvironment induced by CLD-401; IND filing for CLD-401 expected by end... ► Artikel lesen | |
| 08.05. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.04. | Calidi presents cancer therapy data at AACR meeting | 3 | Investing.com | ||
| 20.04. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 | 1 | GlobeNewswire (USA) | ||
| 14.04. | Calidi to present RedTail platform data at Iceland conference | 2 | Investing.com | ||
| 27.03. | Calidi Biotherapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.03. | Calidi BioTherapeutics GAAP EPS of -$5.95 | 2 | Seeking Alpha | ||
| 27.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights | 185 | GlobeNewswire (Europe) | Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trialThe Company has received feedback from the FDA through Type D interactions, and the Company believes its... ► Artikel lesen | |
| 24.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials | 1 | GlobeNewswire (USA) | ||
| 12.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing | 1 | GlobeNewswire (USA) | ||
| 10.03. | Calidi Biotherapeutics closes $6M public offering | 1 | Investing.com | ||
| 10.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option | 1 | GlobeNewswire (USA) | ||
| 06.03. | Calidi BioTherapeutics prices $5.2M underwritten public offering | 1 | Seeking Alpha |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,05 | -1,34 % | BioNTech und BMS melden neue Daten für Lungenkrebskandidat Pumitamig | BioNTech SE und Bristol Myers Squibb haben auf dem ASCO-Jahreskongress in Chicago erste globale Phase-2-Daten für den bispezifischen Immunmodulator Pumitamig in Kombination mit Chemotherapie bei fortgeschrittenem... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 5,820 | -1,02 % | Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher | ||
| PRAXIS PRECISION MEDICINES | 254,00 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 35,590 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| JADE BIOSCIENCES | 16,940 | 0,00 % | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect... ► Artikel lesen | |
| QIAGEN | 31,920 | -2,18 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Feedback aus Gesprächen mit etlichen US-Laborexperten deute darauf hin, dass... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 86,86 | -0,07 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| ADMA BIOLOGICS | 7,970 | 0,00 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 14,755 | -0,10 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| ERASCA | 11,970 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,315 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,720 | +0,13 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 59,28 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | - A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission - IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,520 | 0,00 % | Relay Therapeutics Shares Jump 18% | ||
| BEAM THERAPEUTICS | 29,370 | -0,10 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen |
Das Unternehmen CALIDI BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,165 Euro und damit -0,30 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CALIDI BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.